TrialInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2014

Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).

Günter Emons et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.